

**A V E X A**

Avexa Limited  
ABN 53 108 150 750  
576 Swan Street Richmond  
Victoria Australia 3121

Telephone 61 3 9208 4300  
Facsimile 61 3 9208 4146  
Website [www.avexa.com.au](http://www.avexa.com.au)

## Press Release

### AVEXA ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS

**Melbourne, Australia, 30 June 2009: Avexa Limited (ASX: AVX)** today announced the appointment of Lawrence Gozlan to its Board of Directors, replacing Dr John Sime who is retiring from the board. Dr Sime was appointed to the board as a non-executive director in June 2007, and Mr Gozlan will replace him in this capacity effective immediately.

“We are thrilled to welcome Lawrence to our Board of Directors. His background in the life science industry as both a leading analyst and investor brings a unique and important perspective to our organisation, and we look forward to his guidance and leadership as we continue to grow,” said Nathan Drona, chairman of Avexa. “I would also like to acknowledge John’s significant contribution to the Avexa board over the last two years and wish him well for his future.”

“Avexa is at a critical juncture with apricitabine currently in Phase III trials and the remainder of the pipeline progressing on track. I am excited to work with the company’s management and board of directors as we look to move the products forward through development,” stated Lawrence Gozlan.

Lawrence Gozlan is the CEO and founder of Scientia Capital, a specialised global investment fund focused exclusively on life science. Prior to Scientia, Mr Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at Queensland Investment Corporation (QIC), a fund manager with over \$50 billion AUD under management. He was also the senior biotechnology sell-side analyst on the equities team at Foster Stockbroking, and had corporate finance experience advising life science companies at Deloitte.

#### About Avexa

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of small molecules for the treatment of infectious diseases. Avexa has dedicated resources and funding for key projects including apricitabine (ATC), its HIV integrase program, its HCV polymerase program and an antibiotic program for antibiotic-resistant bacterial infections. The Company’s lead program, ATC, is an anti-HIV drug that has successfully completed the 96 week dosing of its Phase IIb trial and is currently in Phase III trials worldwide.

#### For more information:

Dr Julian Chick  
Chief Executive Officer  
+61 3 9208 4300

Stephen Kerr  
CFO & Company Secretary  
+ 61 3 9208 4300

AU: Investor Relations  
Sabrina Antoniou  
Blueprint Life Science Group  
+ 61 2 9519 5537

US: Investor Relations  
Remy Bernarda  
Blueprint Life Science Group  
+ 1 415 375 3340 x2022

[www.avexa.com.au](http://www.avexa.com.au)